Previous Close | 1.4000 |
Open | 1.3500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 4.00 |
Expire Date | 2025-01-17 |
Day's Range | 1.3500 - 1.4500 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...
17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumpsINHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for pat
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).